THE DAY, IN CONTEXTPolaris InsightsAn AI-powered comprehensive news portal

POLARIS INSIGHTS

Starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027

The development centers on starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while….

Read the full account of the story

More from the Markets desk

More from Markets · Back to Polaris Insights